C-reactive protein in young, apparently healthy men: Associations with serum Leptin, QTc interval, and high-density lipoprotein-cholesterol

Metabolism: Clinical and Experimental

Volumn 52, Issue 9, 2003, Pages 1113-1116

  Kazumi, Tsutomu ^a,b,c,d   Kawaguchi, Akira ^a,b,c,d   Hirano, Tsutomu ^a,b,c,d   Yoshino, Gen ^a,b,c,d  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b KOBE UNIVERSITY OF MERCANTILE MARINE   (Japan)

^c SHOWA UNIVERSITY   (Japan)

^d TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMISTRY; BODY FAT; BODY MASS; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; COLLEGE STUDENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; HEART RATE; HOMEOSTASIS; HUMAN; HYPOCHOLESTEROLEMIA; INFLAMMATION; INSULIN RESISTANCE; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT INTERVAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0141459376     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00184-7     Document Type: Article

References (47)

1. Hotamisligil GC, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
2. Mohamed-Ali V, Goodrich S, Rawesh A, et al: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200, 1997
3. Castell JV, Gomez-Lechon MJ, David M, et al: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 242:237-239, 1989
4. Baumann H, Gauldie J: Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 7:147-159, 1990
5. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 265:621-636, 1990
6. Kuller LH, Tracy RP, Shaten J, et al: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144: 537-547, 1996
7. Mendell MA, Patel P, Ballam L, et al: C reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. Br Med J 312:1061-1065, 1996
8. Haverkate F, Thompson SG, Pyke SDM, et al: Production of C reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462-466, 1997
9. Tracy RP, Psaty BM, Macy E, et al: Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17:2167-2176, 1997
10. Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22;1971-1977, 1999
11. Visser M, Bouter LM, McQuillan GM, et al: Elevated C reactive protein levels in overweight and obese adults. JAMA 282:2131-2135, 1999
12. Yudkin JS, Stehouwer CD, Emeis JJ, et al: C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978, 1999
13. Hak AE, Stehouwer CD, Bots ML, et al: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19:1986-1991, 1999
14. Tracy RP, Lemaitre RN, Psaty B, et al: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Result from the Cardiovascular Healthy Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17:1121-1127, 1997
15. Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
16. Koenig W, Frohlich M, Sund M, et al: C-reactive protein (CRP) predicts risk of coronary heart disease (CHD) in healthy middle-aged men: Results from the MONICA-Augsburg cohort study, 1984-1992. Circulation 99:237-242, 1999
17. Danesh J, Muir J, Wolg Y.-K, et al: Risk factors for coronary heart disease and acute-phase proteins: A population-based study. Eur Heart J 20:954-959, 1999
18. Frohlich M, Imhof A, Berg G, et al: Association between C-reactive protein and features of the metabolic syndrome. A population-based study. Diabetes Care 23:1835-1839, 2000
19. Cook DG, Mendall MA, Whincup PH, et al: C-reactive protein concentration in children: Relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 149:139-150, 2000
20. Danesh J, Whincup P, Lennon L, et al: Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. Br Med J 321:199-204, 2000
21. Chambers JC, Eda S, Bassett P, et al: C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 104:145-150, 1999
22. Friihbeck G, Salvador J: Relation between leptin and glucose metabolism. Diabetologia 43:3-12, 2000
23. Berg AH, Combs TP, Schere PE: ACRP30/ adiponectine: An adiponectine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13:84-89, 2002
24. Kazumi T, Kawaguchi A, Katoh J, et al: Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index. J Hypertens 17:1451-1455, 1999
25. Kazumi T, Kawaguchi A, Hozumi T, et al: Serum HDL cholesterol values are associated with apoB-containing lipoprotein metabolism and triglyceride-body fat interrelation in young Japanese men. Atherosclerosis 130:93-100, 1997
26. McLaughlin NB, Campbell RW, Murray A: Comparison of automated QT measurement techniques in the normal 12 lead electrocardiogram. Br Heart J 74:84-89, 1995
27. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
28. Nichols AV, Krauss RM, Musliner TA: Nondenaturing polyacryl-amide gradients gel electrophoresis, in Segrest JP, Albert JJ, (eds): Methods in Enzymology, Vol 128, Plasma Lipoproteins, Part A, Preparation, Structure and Molecular Biology. Orlando, FL, Academic Press, 1986, pp 417-431
29. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio Heart Study. Diabetes Care 20;1087-1092, 1997
30. Emoto M, Nishizawa Y, Maekawa K, et al: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22:818-822, 1999
31. Hermans MP, Levy JC, Morris RJ, et al: Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42:678-687, 1999
32. Hermans MP, Levy JC, Morris RJ, et al: Comparison of tests of β-cell function across a range of glucose tolerance from normal to diabetes. Diabetologia 42:1779-1786, 1999
33. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study 24. Ann Intern Med 128:165-175, 1998
34. Bomora E, Targher G, Alberiche M, et al.: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 23:57-63, 2000
35. Ledue TB, Weiner DL, Sipe JP, et al.: Analytical evaluation of particle enhanced immuno-nephrometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35:745-753, 1998
36. Arita Y, Kihara S, Ouchi N, et al.: Paradoxical decrease of an adipose specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 257:79-83, 1999
37. Loffreda S, Yang SQ, Lia HZ, et al.: Leptin regulates proinflammatory immune response. FASEB J 12:57-65, 1998
38. Lemieux I, Poscot A, Prud'homme D, et al.: Elevated C-reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 21:961-967, 2001
39. Carella MJ, Mantz SL, Rovner DR, et al: Obesity, adiposity, and lengthening of the QT interval: Improvement after weight loss. Int J Obesity 20:938-942, 1996
40. Dekker JM, Schouten EG, Klootwijk P, et al: Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. Circulation 90:779-785, 1994
41. Kazumi T, Kawaguchi A, Katoh J, et al: Fasting serum insulin concentrations are associated with QTc interval independent of serum leptin, percent body fat, and BMI. Diabetes Care 22:1917-1918, 1999
42. Besedowsky HO, Del Rey A: Immune-neuro-endocrine interactions. Endocr Rev 17:664-102, 1996
43. Festa A, D'Agostino R Jr, Howard G, et al: Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42-47, 2000
44. Radziuk J: Insulin sensitivity and its measurement: Structural commonalities among the methods. J Clin Endocrinol Metab 85:4426-4433, 2000
45. Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectine reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
46. Berg AH, Comts TP, Du X, et al: The adipocyte-secreted protein. Acrp 30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
47. Tietge UJ, Maugeais C, Land-Katz S, et al: Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and Apo A-I in response to inflammation in human apo A-I transgenic mice. Arterioscler Thromb Vasc Biol 22:1213-1218, 2002